PPARδ agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
There are thousands of proteins in any particular cell. An estimated 1/10 to 1/2 of proteins are phosphorylated in some cellular state. 30–65% of proteins in humans and ~50% of proteins in yeast may be phosphorylated. An estimated 230,000, 156,000, and 40,000 phosphorylation sites exist in human, mouse, and yeast, respectively. Phosphorylation often occurs on multiple distinct sites on a given protein. Since phosphorylation of any site on a given protein can change the function or localization of that protein, understanding the "state" of a cell requires knowing the phosphorylation state of its proteins. For example, generally, if amino acid Serine-473 in the protein AKT is phosphorylated, AKT is functionally active as a kinase, and if it is not phosphorylated, AKT is an inactive kinase. Phosphorylation sites are crucial for proteins and their transportation and functions. They are the covalent modification of proteins through reversible phosphorylation. This enables proteins to stay inbound within a cell since the negative phosphorylated site disallows their permeability through the cellular membrane. Protein dephosphorylation allows the cell to replenish phosphates through release of pyrophosphates which saves ATP use in the cell. An example of phosphorylating enzyme is found in E. coli bacteria. It possesses alkaline phosphatase in its periplasmic region of its membrane. The outermost membrane is permeable to phosphorylated molecules however the inner cytoplasmic membrane is impermeable due to large negative charges. In this way, the E.
== Broadband == One of the first DIA approaches was a nozzle-skimmer dissociation method called shotgun collision-induced dissociation (CID). Fragmentation can be in the ion source of the mass spectrometer by increasing the nozzle-skimmer voltage in electrospray ionization. MSE is a broadband DIA technique that uses alternating low-energy CID and high-energy CID. The low-energy CID is used to acquire precursor ion mass spectra whereas the high-energy CID is used to obtain product ion information by tandem mass spectrometry.
This ATP synthesis reaction is called the binding change mechanism and involves the active site of a β subunit cycling between three states. In the "open" state, ADP and phosphate enter the active site (shown in brown in the diagram). The protein then closes up around the molecules and binds them loosely – the "loose" state (shown in red). The enzyme then changes shape again and forces these molecules together, with the active site in the resulting "tight" state (shown in pink) binding the newly produced ATP molecule with very high affinity. Finally, the active site cycles back to the open state, releasing ATP and binding more ADP and phosphate, ready for the next cycle. In some bacteria and archaea, ATP synthesis is driven by the movement of sodium ions through the cell membrane, rather than the movement of protons. Archaea such as Methanococcus also contain the A1Ao synthase, a form of the enzyme that contains additional proteins with little similarity in sequence to other bacterial and eukaryotic ATP synthase subunits. It is possible that, in some species, the A1Ao form of the enzyme is a specialized sodium-driven ATP synthase, but this might not be true in all cases.
Sources: en.wikipedia.org
=== DNA synthesis usage === The term formula weight has a specific meaning when used in the context of DNA synthesis: whereas an individual phosphoramidite nucleobase to be added to a DNA polymer has protecting groups and has its molecular weight quoted including these groups, the amount of molecular weight that is ultimately added by this nucleobase to a DNA polymer is referred to as the nucleobase's formula weight (i.e., the molecular weight of this nucleobase within the DNA polymer, minus protecting groups).
Lab Matters: Each issue of APHL's quarterly magazine, Lab Matters, considers a pressing health issue of importance to public health laboratories. Bridges: Connecting the nation's environmental laboratories, Bridges is APHL's semi-annual newsletter for environmental health professionals. Social Media: APHL is active on Twitter, Facebook and LinkedIn, and has video channels on both YouTube and Vimeo. Blog: APHL's Public Health LabLog features recent and interesting stories about the work of APHL and public health laboratories. 1899: American Public Health Association formed the Committee of Laboratories 1921: Southern Public Health Laboratory Association (SPHLA) formed 1927: SPHLA became State Laboratory Directors Conference and opened membership to other states 1939: SPHLA changed its name to Conference of State and Provincial Laboratory Directors 1951: Association of State and Territorial Public Health Laboratory Directors founded 1998: Renamed the Association of Public Health Laboratories (APHL) and became a more inclusive organization with new membership categories
Moving forward, though, the potential for real biological computers is immense. We are essentially talking about fully-functional computers that can sense their surroundings, and then manipulate their host cells into doing just about anything. Biological computers might be used as an early-warning system for disease, or simply as a diagnostic tool ... Biological computers could tell their host cells to stop producing insulin, to pump out more adrenaline, to reproduce some healthy cells to combat disease, or to stop reproducing if cancer is detected. Biological computers will probably obviate the use of many pharmaceutical drugs. UC Berkeley biochemical engineer Jay Keasling said the transcriptor "clearly demonstrates the power of synthetic biology and could revolutionize how we compute in the future".
Traditionally, Escherichia coli is the choice bacterium to express eukaryotic and recombinant genes. E. coli is well understood and has a successful track record producing insulin, the artemisinin precursor artemisinic acid, and filgrastim (Neupogen). However, use of E. coli has limitations including misfolding of eukaryotic proteins, insolubility issues, deposition in inclusion bodies, low secretion efficiency, secretion to periplasmic space. Streptomyces offers potential advantages including superior secretion mechanisms, higher yields, a simpler end-product purification process, making Streptomyces an attractive alternative to E. coli and Bacillus subtilis. Streptomyces coelicolor, Streptomyces avermitilis, Streptomyces griseus, and Saccharopolyspora erythraea, are capable of secondary metabolite production. Streptomyces coelicolor has shown useful for the heterologous expression of proteins. Methods like "ribosome engineering" have been used to achieve 180-fold higher yields with S. coelicolor.
Sources: en.wikipedia.org
A concentrated coffee/milk/sugar mixture was produced for the Union army during the American Civil War under the name Essence of Coffee, a teaspoonful of which was mixed with a cup of hot water. It had the consistency of axle grease, and proved so unpopular with the troops that it was soon discontinued. The brand Camp Coffee, a liquid coffee and chicory essence, was first produced in 1876 by Paterson & Sons Ltd in Scotland. The invention for powdered soluble instant coffee was filed on 28 January 1889 and patented in 1890, by David Strang of Invercargill, New Zealand, under patent number 3518, and sold as "Strang's Soluble Coffee Powder", citing the patented "Dry Hot-Air" process. Some modern sources have credited French humorist and writer Alphonse Allais with the invention. The invention had previously been attributed to Satori Kato, a Japanese scientist working in Chicago in 1901. Kato introduced the powdered substance in Buffalo, New York, at the Pan-American Exposition. George Constant Louis Washington developed his own instant coffee process shortly thereafter, and first marketed it commercially (1910). The product was expensive in relation to its quality however, and had the disadvantage of being highly hygroscopic. In the 1938 Nestlé produced a more stable, free-flowing instant coffee powder under the Nescafé brand. It had previously not been possible to spray dry coffee extract due to its high levels of low molecular weight sugars and acids. These cause the spray dried powder to become sticky and clump into a paste.
In contrast to functional asymptomatic hyperprolactinemia, the treatment for functional symptomatic hyperprolactinemia is different since stopping antipsychotic drugs for a short trial period is not recommended due to the risk of exacerbation or relapse of symptoms. A systematic review and meta-analysis have shown that options for the treatment of hyperprolactinemia in people with psychotic disorder include decreasing the dose of antipsychotics, adding aripiprazole as an adjunctive therapy, and switching antipsychotics as a last resort. On the other hand, the treatment of hyperprolactinemia in children and adolescents with antipsychotic medications has been studied to provide guidelines, as these medications may adversely affect child growth and development. Results have shown that aripiprazole significantly decreases prolactin levels compared to other medications such as olanzapine and risperidone, which result in increased prolactin levels. Pharmacologic hyperprolactinemia, the concerning drug can be switched to another treatment or discontinued entirely. No treatment is required in asymptomatic macroprolactin and instead, serial prolactin measurements and pituitary imaging are monitored in regular follow-up appointments. Medical therapy is the preferred treatment for prolactinomas. In most cases, medications that are dopamine agonists, such as cabergoline, quinagolide and bromocriptine (often preferred when pregnancy is possible), are the treatment of choice used to decrease prolactin levels and tumor size upon the presence of microadenomas or macroadenomas.
Scouting 'Round the World: a book updated every three years with details on all WOSM member organizations; WorldInfo Archived 11 October 2006 at the Wayback Machine: a monthly circular distributed in electronic format with the help of Scoutnet.
== Further reading == Nualart F, Rivas C, Montecinos V, Godoy A, Guaiquil V, Golde D, Vera J (2003). "Recycling of vitamin C by a bystander effect". J Biol Chem. 278 (12): 10128–33. doi:10.1074/jbc.M210686200. hdl:10533/174378. PMID 12435736.
== Results == The United States Department of Commerce gave 10 Chinese companies, including Alibaba Group, Tencent, ByteDance, and JD.com, and distributors including Lenovo and Foxconn, the permission to purchase NVIDIA's H200 chips. Trump announced that China had agreed to order 200 airplanes from Boeing. Although this is the first Chinese purchase of airplanes manufactured from U.S. companies since an order of 300 airplanes was made during Trump's previous state visit to China in 2017, this was below the 500 airplanes that the industry had discussed. After the visit, Trump had an interview with Fox News where he warned Taiwan against independence, saying "I'm not looking to have somebody go independent" and "we're not looking to have somebody say, 'Let's go independent because the United States is backing us.'"
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.